Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for SNY

Stock NameSanofi ADR
TickerSNY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS80105N1054
LEI549300E9PC51EN656011

Show aggregate SNY holdings

News associated with SNY

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Sanofi (NASDAQ:SNY) Shares Acquired Rep. Lisa C. McClain
Representative Lisa C. McClain (R-Michigan) recently bought shares of Sanofi (NASDAQ:SNY). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Sanofi stock on August 4th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account. Representative Lisa C. McClain also recently made the […] - 2025-09-17 03:08:42
Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study
(RTTNews) - Sanofi (SNY) announced promising new data from its HS-OBTAIN phase 2a study, highlighting the efficacy of brivekimig in treating biologic-naïve patients with moderate-to-severe hidradenitis suppurativa (HS). - 2025-09-17 02:33:17
Sanofi: FDA Grants Fast Track Designation For SAR402663
(RTTNews) - Sanofi said the FDA has granted fast track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration. Sanofi is currently evaluating SAR402663 in a phase 1/2 for the treatment of p - 2025-09-11 02:36:46
Morgan Stanley Upgrades Sanofi (NASDAQ:SNY) to “Overweight”
Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued on Monday, Marketbeat.com reports. The firm currently has a $58.00 target price on the stock, up from their previous target price of $56.00. Morgan Stanley’s target price suggests a potential […] - 2025-09-10 03:00:55
Why Nektar Therapeutics Rippled Higher This Week
Key PointsInvestors are pricing in a better commercial outcome for a drug that isn't even in phase 3 yet. - 2025-09-05 14:32:33
Sanofi's Amlitelimab Meets Primary & Key Secondary Endpoints In Phase 3 Study For Atopic Dermatitis
(RTTNews) - Sanofi SA's (SAN.PA, SNYNF, SNY) investigational therapy, amlitelimab, has achieved a significant milestone in the COAST 1 phase 3 clinical trial, meeting all primary and key secondary endpoints in adults and adolescents with moderate-to-severe atopic dermatitis. Admi - 2025-09-04 02:27:43
Implied PID Analyst Target Price: $23
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-03 08:00:10
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 253 Shares of Sanofi (NASDAQ:SNY)
Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Sanofi (NASDAQ:SNY – Free Report) by 6.7% in the 1st quarter, HoldingsChannel reports. The firm owned 4,032 shares of the company’s stock after buying an additional 253 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Sanofi were worth $224,000 as of […] - 2025-08-15 04:47:04
Atria Wealth Solutions Inc. Sells 1,794 Shares of Sanofi (NASDAQ:SNY)
Atria Wealth Solutions Inc. decreased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 10.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,855 shares of the company’s stock after selling 1,794 shares during the quarter. Atria Wealth Solutions Inc.’s holdings […] - 2025-08-12 05:09:02
Sanofi (NASDAQ:SNY) Rating Increased to Buy at Wall Street Zen
Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY – Free Report) from a hold rating to a buy rating in a report published on Saturday morning. Other research analysts have also issued reports about the company. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Barclays reaffirmed […] - 2025-08-05 02:56:56
Analyzing Sanofi (NASDAQ:SNY) and Roche (OTCMKTS:RHHBY)
Sanofi (NASDAQ:SNY – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership. Valuation & Earnings This table compares Sanofi and Roche”s […] - 2025-08-04 04:30:52
The Math Shows FVD Can Go To $50
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-31 09:19:44
Sanofi (NASDAQ:SNY) versus Roche (OTCMKTS:RHHBY) Critical Comparison
Sanofi (NASDAQ:SNY – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Insider and Institutional Ownership 14.0% of Sanofi shares are […] - 2025-07-30 03:02:41
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
Key PointsArtificial intelligence-powered drug development isn't a mere premise anymore. Recursion Pharmaceuticals has made it a reality. - 2025-07-26 19:14:00
Sanofi's Sarclisa Combination Gets EU Approval For Treating Newly Diagnosed Multiple Myeloma
(RTTNews) - Sanofi Winthrop Industrie said that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for auto - 2025-07-25 02:16:12
Sanofi (NASDAQ:SNY) Shares Sold by Choreo LLC
Choreo LLC lowered its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 21.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,889 shares of the company’s stock after selling 12,555 shares during the period. Choreo LLC’s holdings in Sanofi were worth […] - 2025-07-24 08:28:55
Sanofi's SAR446597 Granted FDA Fast Track For Gene Therapy Tackling Vision Loss In AMD
(RTTNews) - Sanofi S.A. (SNYNF,SNY) said that the U.S. Food and Drug Administration has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration or AMD. - 2025-07-16 02:29:02
Cerity Partners LLC Has $10.91 Million Holdings in Sanofi (NASDAQ:SNY)
Cerity Partners LLC increased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 62.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 196,726 shares of the company’s stock after buying an additional 75,698 shares during the quarter. Cerity Partners LLC’s […] - 2025-07-15 08:30:17
Concurrent Investment Advisors LLC Decreases Stock Holdings in Sanofi (NASDAQ:SNY)
Concurrent Investment Advisors LLC trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 74.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,700 shares of the company’s stock after selling 28,246 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in […] - 2025-07-11 05:50:49
Bank of New York Mellon Corp Sells 840,093 Shares of Sanofi (NASDAQ:SNY)
Bank of New York Mellon Corp lowered its position in Sanofi (NASDAQ:SNY – Free Report) by 30.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,945,223 shares of the company’s stock after selling 840,093 shares during the quarter. Bank of New York […] - 2025-07-10 05:35:08
Leerink Partnrs Estimates Sanofi’s Q2 Earnings (NASDAQ:SNY)
Sanofi (NASDAQ:SNY – Free Report) – Stock analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Sanofi in a research report issued to clients and investors on Monday, July 7th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of $0.94 for the quarter, […] - 2025-07-10 02:17:01
Financial Review: Sanofi (NASDAQ:SNY) & Merck & Co., Inc. (NYSE:MRK)
Sanofi (NASDAQ:SNY – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends. Insider and Institutional Ownership 14.0% of […] - 2025-07-09 05:36:55
Leerink Partnrs Predicts Sanofi’s Q3 Earnings (NASDAQ:SNY)
Sanofi (NASDAQ:SNY – Free Report) – Research analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for Sanofi in a report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of $1.77 per share for the quarter, up from their previous estimate of $1.76. The […] - 2025-07-09 02:10:51
Private Trust Co. NA Purchases 697 Shares of Sanofi (NASDAQ:SNY)
Private Trust Co. NA raised its position in Sanofi (NASDAQ:SNY – Free Report) by 19.8% in the 1st quarter, Holdings Channel reports. The firm owned 4,220 shares of the company’s stock after buying an additional 697 shares during the quarter. Private Trust Co. NA’s holdings in Sanofi were worth $234,000 at the end of the […] - 2025-07-08 04:52:56
Analysts Set Sanofi (NASDAQ:SNY) Price Target at $61.50
Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and three have assigned a strong buy rating to […] - 2025-07-02 02:22:53
Sanofi (NASDAQ:SNY) Shares Sold by Transcend Capital Advisors LLC
Transcend Capital Advisors LLC lowered its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 30.7% in the first quarter, HoldingsChannel reports. The fund owned 3,895 shares of the company’s stock after selling 1,728 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Sanofi were worth $216,000 at the end of the most […] - 2025-07-01 05:26:59
Sequoia Financial Advisors LLC Increases Stake in Sanofi (NASDAQ:SNY)
Sequoia Financial Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 15.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 24,272 shares of the company’s stock after purchasing an additional 3,269 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,346,000 at the […] - 2025-06-30 05:37:03
Sanofi's Riliprubart Secures U.S. Orphan Drug Status For Solid Organ Transplant Rejection
(RTTNews) - The U.S. Food and Drug Administration has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation, Sanofi Winthrop Industrie said in a statement. - 2025-06-25 02:39:22
Sanofi's Sarclisa Recommended For EU Approval To Treat Transplant-eligible Newly Diagnosed MM
(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced Monday that Sarclisa (isatuximab) has been recommended for European Union approval by the Committee for Medicinal Products for Human Use or CHMP to treat transplant-eligible newly diagnosed multiple myeloma, based on - 2025-06-23 02:53:56

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) SNY holdings

DateNumber of SNY Shares HeldBase Market Value of SNY SharesLocal Market Value of SNY SharesChange in SNY Shares HeldChange in SNY Base ValueCurrent Price per SNY Share HeldPrevious Price per SNY Share Held
2025-11-11 (Tuesday)174,219USD 9,005,380USD 9,005,380
2025-11-10 (Monday)174,219SNY holding increased by 445USD 8,825,935SNY holding increased by 196318USD 8,825,935445USD 196,318 USD 50.66 USD 49.66
2025-11-07 (Friday)173,774USD 8,629,617SNY holding increased by 29542USD 8,629,6170USD 29,542 USD 49.66 USD 49.49
2025-11-06 (Thursday)173,774SNY holding increased by 445USD 8,600,075SNY holding increased by 106954USD 8,600,075445USD 106,954 USD 49.49 USD 49
2025-11-05 (Wednesday)173,329USD 8,493,121SNY holding decreased by -19066USD 8,493,1210USD -19,066 USD 49 USD 49.11
2025-11-04 (Tuesday)173,329SNY holding increased by 447USD 8,512,187SNY holding decreased by -140557USD 8,512,187447USD -140,557 USD 49.11 USD 50.05
2025-11-03 (Monday)172,882USD 8,652,744SNY holding decreased by -91628USD 8,652,7440USD -91,628 USD 50.05 USD 50.58
2025-10-31 (Friday)172,882USD 8,744,372SNY holding decreased by -62237USD 8,744,3720USD -62,237 USD 50.58 USD 50.94
2025-10-30 (Thursday)172,882SNY holding increased by 2235USD 8,806,609SNY holding increased by 158219USD 8,806,6092,235USD 158,219 USD 50.94 USD 50.68
2025-10-29 (Wednesday)170,647SNY holding increased by 1602USD 8,648,390SNY holding increased by 16952USD 8,648,3901,602USD 16,952 USD 50.68 USD 51.06
2025-10-28 (Tuesday)169,045USD 8,631,438SNY holding decreased by -59165USD 8,631,4380USD -59,165 USD 51.06 USD 51.41
2025-10-27 (Monday)169,045USD 8,690,603SNY holding decreased by -38881USD 8,690,6030USD -38,881 USD 51.41 USD 51.64
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SNY by Blackrock for IE00BYXG2H39

Show aggregate share trades of SNY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY445 50.660* 51.46
2025-11-06BUY445 49.490* 51.47
2025-11-04BUY447 49.110* 51.50
2025-10-30BUY2,23551.33050.835 50.884USD 113,727 51.52
2025-10-29BUY1,60250.68051.635 51.539USD 82,566 51.52
2025-10-22SELL-1,78049.99050.480 50.431USD -89,767 51.54 Profit of 1,976 on sale
2025-10-20BUY89049.73050.510 50.432USD 44,884 51.56
2025-10-17BUY2,22350.62050.720 50.710USD 112,728 51.57
2025-10-15BUY3,54448.96049.160 49.140USD 174,152 51.58
2025-10-03BUY3,08750.90051.050 51.035USD 157,545 51.60
2025-10-02BUY44150.14050.350 50.329USD 22,195 51.61
2025-09-30BUY88247.20047.220 47.218USD 41,646 51.64
2025-09-26BUY88245.54045.840 45.810USD 40,404 51.71
2025-09-25BUY88245.07045.700 45.637USD 40,252 51.75
2025-09-24SELL-15,23146.40047.000 46.940USD -714,943 51.78 Profit of 73,723 on sale
2025-09-18BUY48447.68048.000 47.968USD 23,217 51.80
2025-09-17BUY1,45846.97047.330 47.294USD 68,955 51.83
2025-08-20SELL-1,94450.53051.240 51.169USD -99,473 51.89 Profit of 1,406 on sale
2025-07-30BUY1,94449.25049.330 49.322USD 95,882 52.02
2025-07-17SELL-97248.65048.650 48.650USD -47,288 52.19 Profit of 3,437 on sale
2025-07-16BUY1,66348.52048.750 48.727USD 81,033 52.21
2025-07-11SELL-3,84848.61048.750 48.736USD -187,536 52.29 Profit of 13,666 on sale
2025-07-07BUY1,44348.32048.520 48.500USD 69,986 52.39
2025-07-02BUY26,45549.31049.370 49.364USD 1,305,925 52.44
2025-06-20BUY1,23547.86048.110 48.085USD 59,385 52.47
2025-06-11BUY95449.70050.060 50.024USD 47,723 52.65
2025-06-10BUY95449.88050.160 50.132USD 47,826 52.68
2025-06-04SELL-47749.50049.770 49.743USD -23,727 52.76 Profit of 1,441 on sale
2025-04-23BUY47753.02053.090 53.083USD 25,321 52.96
2025-04-10SELL-3,81649.66050.210 50.155USD -191,391 53.16 Profit of 11,468 on sale
2025-04-08SELL-47749.86051.340 51.192USD -24,419 53.22 Profit of 968 on sale
2025-04-07SELL-47750.76052.190 52.047USD -24,826 53.25 Profit of 573 on sale
2025-04-04SELL-2,38551.98053.860 53.672USD -128,008 53.26 Loss of -973 on sale
2025-04-01BUY3,83054.34055.500 55.384USD 212,121 53.24
2025-03-31SELL-1,41055.46055.620 55.604USD -78,402 53.22 Loss of -3,367 on sale
2025-03-14SELL-7,53657.75057.930 57.912USD -436,425 52.65 Loss of -39,669 on sale
2025-03-07SELL-94259.25059.660 59.619USD -56,161 52.20 Loss of -6,988 on sale
2025-03-04SELL-47157.70057.840 57.826USD -27,236 51.89 Loss of -2,797 on sale
2025-02-25BUY94254.89055.000 54.989USD 51,800 51.62
2025-02-19SELL-47153.60053.750 53.735USD -25,309 51.45 Loss of -1,078 on sale
2025-02-13BUY1,41053.99055.040 54.935USD 77,458 51.22
2025-02-12BUY47054.56054.870 54.839USD 25,774 51.15
2025-02-11BUY1,88053.90054.000 53.990USD 101,501 51.10
2024-12-30SELL-12,50148.23048.650 48.608USD -607,649 50.45 Profit of 23,072 on sale
2024-11-18SELL-7,54548.51048.670 48.654USD -367,094 52.76 Profit of 31,018 on sale
2024-11-08SELL-50351.32051.620 51.590USD -25,950 53.06 Profit of 737 on sale
2024-10-30BUY52553.45053.720 53.693USD 28,189 53.48
2024-10-21SELL-50153.66054.650 54.551USD -27,330 0.00 Loss of -27,330 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SNY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19813,24301,931,04442.1%
2025-09-18441,6570990,36444.6%
2025-09-17494,3967,1071,168,80142.3%
2025-09-16370,5651805,10046.0%
2025-09-15315,1606391,296,51724.3%
2025-09-12674,6651121,437,85246.9%
2025-09-11346,6910839,95541.3%
2025-09-10386,771893733,77752.7%
2025-09-09307,08901,182,30626.0%
2025-09-08354,047281,638,24321.6%
2025-09-05911,7553,2733,562,99925.6%
2025-09-041,219,2507,8593,695,06533.0%
2025-09-03468,32977865,04454.1%
2025-09-02776,6491,3491,006,02077.2%
2025-08-29615,744300866,98371.0%
2025-08-28249,3942648,15938.5%
2025-08-27352,24428910,40338.7%
2025-08-26283,779333585,67448.5%
2025-08-25483,5151,600729,78066.3%
2025-08-22376,931100719,51552.4%
2025-08-21408,6394,290628,40565.0%
2025-08-20432,60536656,74965.9%
2025-08-19333,115451632,81652.6%
2025-08-18636,0825,4911,330,26047.8%
2025-08-15444,632308985,36145.1%
2025-08-14450,2077311,543,05129.2%
2025-08-13364,5114581,78562.7%
2025-08-12375,6811,200586,21564.1%
2025-08-11595,5258,3001,152,71151.7%
2025-08-08659,9292,4001,312,51150.3%
2025-08-07976,538111,701,32557.4%
2025-08-061,016,4984,5221,527,43366.5%
2025-08-05774,1224,8741,207,82664.1%
2025-08-04672,3331,5531,193,40756.3%
2025-08-01680,9532,1321,296,10852.5%
2025-07-311,876,4462,1754,218,17544.5%
2025-07-30499,8880902,31755.4%
2025-07-29987,98601,653,49659.8%
2025-07-28350,7420964,84536.4%
2025-07-25190,58984681,54228.0%
2025-07-24242,3342726,58233.4%
2025-07-23367,937243877,77341.9%
2025-07-22228,781267509,40944.9%
2025-07-21241,7230634,80738.1%
2025-07-18229,451900578,32039.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.